Fergus Keane
@ferguskeane2
Followers
738
Following
3K
Media
15
Statuses
314
RT @DrAngelaLamarca: Great overview of #PrecisionMedicine in #PDAC by @EileenMOReilly at @myESMO #ESMOGI25. If you missed it, please watch….
0
35
0
Congrats to oncology trainee Mary O’Reilly presenting data from her PhD on early onset colorectal cancer at ESMO GI 2025 @myESMO @RayMcDermott1 @graokane @svuh
0
11
63
RT @graokane: Optimal approach in BR-PDAC/LAPC.✅starting with neoadjuvant therapy.❓is there a role for switch tx ?PAXG?.❓how do we incorpor….
0
5
0
RT @Seamusoreilly18: 📣#ASCO25 distilled by @cancertrials_ie hosted ISMO ☘️ webinar: . Top 3 abstracts 📃 by tumor type✅. Single slide summar….
0
18
0
RT @graokane: 🔥POLCAGB Ph 3 neoadjuvant chemo vs neoadjuvant chemorads + chemo in locally adv GBC.➡️ closed at interim due to poor accrual….
0
19
0
RT @NEJM: Original Article: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (BREAKWATER phase 3 trial) https://t.co/….
0
61
0
RT @Annals_Oncology: 🆕ESMO guideline podcast🎧: Annals of Oncology Editor-in-Chief @tompowles1 discusses the ESMO ESMO Clinical Practice Gui….
0
16
0
RT @MichaelLaPelusa: (1/6) Hot off the press in @NatureComms! Pembrolizumab delivers durable responses for patients with localized dMMR/MSI….
0
35
0
RT @shahid_pmc: Well done to Karine and the team on this excellent poster, which highlights the financial and resource implications of geno….
0
4
0
RT @Erman_Akkus: 💉Full publication of CheckMate-9DW.Nivolumab plus ipilimumab versus lenvatinib or sorafenib in 1L treatment of advanced HC….
0
38
0
RT @EASLnews: This afternoon at #EASLCongress, experts are taking on the complexities of hepatocellular carcinoma management in a fast-evol….
0
4
0
RT @MikeFooteMD: New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz).•100 % cCR in 49 re….
0
20
0
RT @BCLC_group: Cardiovascular events in patients with HCC treated with IOs: A nice multicenter study coordinated f….
0
17
0
RT @TheLancet: Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-rel….
0
125
0
RT @CancerInstIRE: Delighted to see Dr. Emily Harrold, Consultant Oncologist, @stjamesdublin & Co- Director of the Young Onset Cancer Prog….
0
6
0
RT @OUCHIntl: Cancer care’s climate cost is rising. 🌎.Dr. Emer Lynch & team, with OUCH’s Dr. Seamus O'Reilly as senior author, outlines key….
0
5
0
RT @Lynchsyndromirl: Mainstreaming cancer genetics: feasibility of an advanced nurse practitioner-led service diagnosing Lynch syndrome … h….
0
5
0
RT @clivejmiranda: Fascinating 🗣️ by @EileenMOReilly on setting the landscape on multimodal oncologic therapies to tackle pancreatic cancer….
0
5
0
RT @TFStoop: Published in @TheLancet, our review on #PancreaticCancer.📎Epidemiology🌎 .📎Pathogenesis🔬 .📎Risk factors & surveillance🕵️ .📎Diag….
0
64
0